tetano
Editor, Senior Moderator
Antiviral Res. 2019 Jun 24:104545. doi: 10.1016/j.antiviral.2019.104545. [Epub ahead of print]
[h=1]Antivirals targeting the polymerase complex of influenza viruses.[/h] Mifsud EJ[SUP]1[/SUP], Hayden FG[SUP]2[/SUP], Hurt AC[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current influenza antivirals have limitations with regard to their effectiveness and the potential emergence of resistance. Encouragingly, several new compounds which inhibit the polymerase of influenza viruses have recently been shown to have enhanced pre-clinical and clinical effectiveness compared to the neuraminidase inhibitors, the mainstay of influenza antiviral therapy over the last two decades. In this review we focus on four compounds which inhibit polymerase function, baloxavir marboxil, favipiravir, pimodivir and AL-794 and discuss their clinical and virological effectiveness, their propensity to select for resistance and their potential for future combination therapy with the most commonly used neuraminidase inhibitor, oseltamivir.
Copyright ? 2019. Published by Elsevier B.V.
PMID: 31247246 DOI: 10.1016/j.antiviral.2019.104545
[h=1]Antivirals targeting the polymerase complex of influenza viruses.[/h] Mifsud EJ[SUP]1[/SUP], Hayden FG[SUP]2[/SUP], Hurt AC[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current influenza antivirals have limitations with regard to their effectiveness and the potential emergence of resistance. Encouragingly, several new compounds which inhibit the polymerase of influenza viruses have recently been shown to have enhanced pre-clinical and clinical effectiveness compared to the neuraminidase inhibitors, the mainstay of influenza antiviral therapy over the last two decades. In this review we focus on four compounds which inhibit polymerase function, baloxavir marboxil, favipiravir, pimodivir and AL-794 and discuss their clinical and virological effectiveness, their propensity to select for resistance and their potential for future combination therapy with the most commonly used neuraminidase inhibitor, oseltamivir.
Copyright ? 2019. Published by Elsevier B.V.
PMID: 31247246 DOI: 10.1016/j.antiviral.2019.104545